CD39: the Potential Target in Small Cell Lung Cancer

Overview

Journal Transl Lung Cancer Res

Date 2020 Sep 21

PMID 32953520

Citations 7

Authors

Shanhao Chen

Shengyu Wu

Liping Zhang

Wei Zhang

Yu Liu

Bin Chen

Sha Zhao

Wei Li

Chenglong Sun

Lei Wang

Keyi Jia

Hao Wang

Peixin Chen

Chunyan Wu

Junjie Zhu

Yayi He

Caicun Zhou

Affiliations

Soon will be listed here.

Abstract

Background: It has been proven that the treatment window of small cell lung cancer (SCLC) is short, so it is vital to find other possible therapeutic targets. CD39 inhibits natural killer (NK) cells and promotes the occurrence and metastasis of tumors. There has been little research about the role of CD39 in SCLC, so we explored the correlation between CD39 and other surface antigens, and its association with survival in SCLC.

Methods: This study included 75 patients with SCLC from Shanghai Pulmonary Hospital. After paraffin embedding and sectioning, immunohistochemistry (IHC) was applied. Then we identify cutoff value for CD39 and other surface antigens based on the analysis of ROC curve in RFS by SPSS. All statistical analyses were based on SPSS and Graphpad Prism8. Chi-square test, Kendall's tau-b correlation analysis, Logistic regression analysis, Kaplan-Meier method, univariate and multivariate Cox regression analysis were conducted. In all analyses, P = 0.05 distinguished whether they had statistical significance.

Results: Of the 75 SCLC patients enrolled in this study, 61.33% positively expressed CD39. A correlation between CD39 and programmed cell death-ligand 1 (PD-L1) (P=0.007), CD3 (P<0.001), CD4 (P<0.001), CD8 (P<0.001), and forkhead box P3 (FOXP3) (P<0.001) on tumor-infiltrating lymphocytes (TILs) was identified by correlation analysis and logistic regression analysis. Based on Kaplan-Meier survival analysis, we found that CD39 affected relapse-free survival (RFS) [negative positive, 95% confidence interval (CI): 0.2765-0.9862, P=0.0390]. SCLC patients with high-expressed CD39 and low-expressed PD-L1 had poor prognosis (P<0.001). Positive expression of CD39 and negative expression of CD3, CD4, CD8, and FOXP3 also indicated shorter RFS (P=0.0409). Univariate and multivariate Cox regression analysis was performed to confirm the factors that influenced RFS.

Conclusions: CD39, programmed cell death-1 (PD-1), and PD-L1 expressed on TILs but not on tumor cells. CD39 has a significant association with PD-L1, CD3, CD4, CD8, and FOXP3 on TILs. The positive expression of CD39 predicts poor prognosis. SCLC patients with low expression of CD39 combined with high expression of PD-L1 or CD3, CD4, CD8, and FOXP3 have a more favorable prognosis.

Citing Articles

CD39 identifies a specific CD8 + T cell population in lung adenocarcinoma-related metastatic pleural effusion.

Lv L, Wang H, Zhang Y, Zhai J, Shen Y, Qu Q BMC Immunol. 2023; 24(1):53.

PMID: 38087217 PMC: 10717623. DOI: 10.1186/s12865-023-00590-z.

Tumour-infiltrating lymphocytes: from prognosis to treatment selection.

Brummel K, Eerkens A, de Bruyn M, Nijman H Br J Cancer. 2022; 128(3):451-458.

PMID: 36564565 PMC: 9938191. DOI: 10.1038/s41416-022-02119-4.

Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.

Wang D, Wu X, Sun Y Signal Transduct Target Ther. 2022; 7(1):331.

PMID: 36123348 PMC: 9485144. DOI: 10.1038/s41392-022-01136-2.

CCL5 as a Prognostic Marker for Survival and an Indicator for Immune Checkpoint Therapies in Small Cell Lung Cancer.

Tang Y, Hu Y, Niu Y, Sun L, Guo L Front Med (Lausanne). 2022; 9:834725.

PMID: 35252266 PMC: 8891515. DOI: 10.3389/fmed.2022.834725.

Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment.

Chen P, Wang H, Zhao L, Guo H, Zhang L, Zhang W Front Oncol. 2021; 11:713853.

PMID: 34900670 PMC: 8652148. DOI: 10.3389/fonc.2021.713853.

References

Simoni Y, Becht E, Fehlings M, Loh C, Koo S, Teng K . Bystander CD8 T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018; 557(7706):575-579. DOI: 10.1038/s41586-018-0130-2. View

Antonia S, Lopez-Martin J, Bendell J, Ott P, Taylor M, Eder J . Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016; 17(7):883-895. DOI: 10.1016/S1470-2045(16)30098-5. View

Sadeghipour A, Babaheidarian P . Making Formalin-Fixed, Paraffin Embedded Blocks. Methods Mol Biol. 2018; 1897:253-268. DOI: 10.1007/978-1-4939-8935-5_22. View

Gabrielson A, Wu Y, Wang H, Jiang J, Kallakury B, Gatalica Z . Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC. Cancer Immunol Res. 2016; 4(5):419-30. PMC: 5303359. DOI: 10.1158/2326-6066.CIR-15-0110. View

Chen P, Kuang P, Wang L, Li W, Chen B, Liu Y . Mechanisms of drugs-resistance in small cell lung cancer: DNA-related, RNA-related, apoptosis-related, drug accumulation and metabolism procedure. Transl Lung Cancer Res. 2020; 9(3):768-786. PMC: 7354133. DOI: 10.21037/tlcr-19-547. View

Sequeira I, Neves J, Carrero D, Peng Q, Palasz N, Liakath-Ali K . Immunomodulatory role of Keratin 76 in oral and gastric cancer. Nat Commun. 2018; 9(1):3437. PMC: 6109110. DOI: 10.1038/s41467-018-05872-4. View

Roth B, Johnson D, Einhorn L, Schacter L, Cherng N, Cohen H . Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992; 10(2):282-91. DOI: 10.1200/JCO.1992.10.2.282. View

Rohaan M, van den Berg J, Kvistborg P, Haanen J . Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option. J Immunother Cancer. 2018; 6(1):102. PMC: 6171186. DOI: 10.1186/s40425-018-0391-1. View

Gazdar A, Bunn P, Minna J . Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017; 17(12):725-737. DOI: 10.1038/nrc.2017.87. View

10.

Li J, Duan X, Wang L, Xu Y, Huang L, Zhang T . Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer. J Immunol Res. 2014; 2014:286170. PMC: 4020463. DOI: 10.1155/2014/286170. View

11.

Waqar S, Morgensztern D . Treatment advances in small cell lung cancer (SCLC). Pharmacol Ther. 2017; 180:16-23. DOI: 10.1016/j.pharmthera.2017.06.002. View

12.

Tondell A, Wahl S, Sponaas A, Sorhaug S, Borset M, Haug M . Ectonucleotidase CD39 and Checkpoint Signalling Receptor Programmed Death 1 are Highly Elevated in Intratumoral Immune Cells in Non-small-cell Lung Cancer. Transl Oncol. 2019; 13(1):17-24. PMC: 6872777. DOI: 10.1016/j.tranon.2019.09.003. View

13.

Syed Khaja A, Toor S, El Salhat H, Ali B, Elkord E . Intratumoral FoxP3Helios Regulatory T Cells Upregulating Immunosuppressive Molecules Are Expanded in Human Colorectal Cancer. Front Immunol. 2017; 8:619. PMC: 5445103. DOI: 10.3389/fimmu.2017.00619. View

14.

Rao S, Yang H, Penninger J, Kroemer G . Autophagy in non-small cell lung carcinogenesis: A positive regulator of antitumor immunosurveillance. Autophagy. 2014; 10(3):529-31. PMC: 4077894. DOI: 10.4161/auto.27643. View

15.

Owonikoko T, Dahlberg S, Sica G, Wagner L, Wade 3rd J, Srkalovic G . Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. J Clin Oncol. 2018; 37(3):222-229. PMC: 6338394. DOI: 10.1200/JCO.18.00264. View

16.

He Y, Yu H, Rozeboom L, Rivard C, Ellison K, Dziadziuszko R . LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. J Thorac Oncol. 2017; 12(5):814-823. DOI: 10.1016/j.jtho.2017.01.019. View

17.

Yoon H, Shi Q, Heying E, Muranyi A, Bredno J, Ough F . Intertumoral Heterogeneity of CD3 and CD8 T-Cell Densities in the Microenvironment of DNA Mismatch-Repair-Deficient Colon Cancers: Implications for Prognosis. Clin Cancer Res. 2018; 25(1):125-133. PMC: 6320300. DOI: 10.1158/1078-0432.CCR-18-1984. View

18.

Ott P, Elez E, Hiret S, Kim D, Morosky A, Saraf S . Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. J Clin Oncol. 2017; 35(34):3823-3829. DOI: 10.1200/JCO.2017.72.5069. View

19.

Sade-Feldman M, Yizhak K, Bjorgaard S, Ray J, de Boer C, Jenkins R . Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018; 175(4):998-1013.e20. PMC: 6641984. DOI: 10.1016/j.cell.2018.10.038. View

20.

Yost K, Satpathy A, Wells D, Qi Y, Wang C, Kageyama R . Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med. 2019; 25(8):1251-1259. PMC: 6689255. DOI: 10.1038/s41591-019-0522-3. View